Anupam Rasayan Denies Stake Purchase Plans in Bliss GVS Pharma

India’s specialty chemicals major, Anupam Rasayan India Ltd, has refuted claims of any stake purchase in Bliss GVS Pharma. The denial follows speculative reports aired on February 13, 2026, which suggested Anupam Rasayan was in advanced talks to acquire a stake in the pharmaceutical firm.

Why This Matters

The clarification is crucial for investors, as the rumor had sparked volatility in Bliss GVS Pharma’s stock price. By addressing the speculation, both companies have reinforced transparency and regulatory compliance, ensuring stakeholders are not misled by unverified market chatter.

Key Highlights

• Speculative Reports: Media reports suggested Anupam Rasayan might acquire a stake in Bliss GVS Pharma.
• Company Denial: Anupam Rasayan confirmed no such deal is under consideration.
• Bliss GVS Response: Bliss GVS Pharma also clarified to NSE and BSE that no arrangement has been finalized.
• Market Impact: Bliss GVS shares surged temporarily on speculation before the official denial.
• Investor Assurance: Both firms emphasized adherence to disclosure norms and transparency.

Final Note
This episode highlights the importance of verified communication in capital markets. Anupam Rasayan’s denial and Bliss GVS Pharma’s clarification ensure investors remain guided by facts, not speculation.

Sources: CNBC Awaaz, Bliss GVS Pharma NSE/BSE filings, FilingReader Intelligence